Mutations in the PPP6C catalytic subunit of protein phosphatase 6 (PP6) are drivers for the development of melanoma. Here, we analyse a panel of melanoma-associated mutations in PPP6C and find that these generally compromise assembly of the PP6 holoenzyme and catalytic activity towards a model substrate. Detailed analysis of one mutant, PPP6C-H114Y, in both primary melanoma and engineered cell lines reveals it is destabilized and undergoes increased proteasome-mediated turnover. Global analysis of phosphatase substrates by mass spectrometry identifies the oncogenic kinase Aurora-A as the major PP6 substrate that is dysregulated under these conditions. Accordingly, cells lacking PPP6C or carrying the PPP6C-H114Y allele have elevated Aurora-A kinase activity and display chromosome instability with associated Aurora-A-dependent micronucleation. Chromosomes mis-segregated to these micronuclei are preferentially stained by the DNA damage marker c-H2AX, suggesting that loss of PPP6C promotes both chromosome instability and DNA damage. These findings support the view that formation of micronuclei rather than chromosome instability alone explains how loss of PPP6C, and more generally mitotic spindle and centrosome defects, can act as drivers for genome instability in melanoma and other cancers.
Introduction
Genomic instability is considered a driving force for a number of human malignancies including cancers (Gordon et al., 2012; Kops et al., 2005; Thompson et al., 2010) . Because of this there is an intense research focus aimed at understanding both how a stable genome is maintained and how increased genome instability can be exploited by targeting pathways that differentiate normal and cancer cells. Alterations in multiple pathways can promote genomic instability and these can be grouped into S-phase pathways important for DNA replication and repair of DNA damage, and M-phase pathways important for accurate genome segregation. In the case of M-phase pathways, mutations or overexpression of proteins involved in centrosome function, sister chromatid cohesion, and mutations in spindle checkpoint associated proteins and other components of the mitotic machinery all lead to increased genome instability (Cahill et al., 1998; Kops et al., 2005; Thompson et al., 2010; Zhou et al., 1998) . Of the mitotic regulators, the Aurora-A mitotic kinase is the best understood in terms of its impact in human cancers. Aurora-A is amplified or upregulated in a wide range of malignancies including cancers of the pancreas, colon, breast, liver and stomach, and it has been proposed that this may constitute a major driver in the pathway to chromosomal instability (Bischoff et al., 1998; Karthigeyan et al., 2010; Lens et al., 2010; Lentini et al., 2007; Sen et al., 1997; Zhou et al., 1998) . Aurora-A has therefore been formally classified as an oncogene (Bischoff et al., 1998) . This has suggested that inhibition of Aurora kinase activity may be useful in the treatment of human cancers and led to the development of specific drugs targeting Aurora-A and B (Lens et al., 2010) . Early pre-clinical investigations of Aurora-A and Aurora B kinase inhibitors have demonstrated promising results and phase I/II trials investigating a number of these compounds are underway (Lens et al., 2010) .
Recent evidence suggests that mutations in the catalytic subunit of protein phosphatase 6 are found in 9 to 12.4% of melanomas surveyed and may act as drivers for the development of melanoma (Hodis et al., 2012; Krauthammer et al., 2012) . At present the basis for this driver effect remains unclear due to the lack of data on the consequence these mutations have for PP6 activity and the limited information about PP6 substrates. PP6 is reported to act in the regulation of NF-kappaB, DNA-dependant protein kinase (DNA-PK), histone c-H2AX and Aurora-A (Douglas et al., 2010; Mi et al., 2009; Stefansson and Brautigan, 2006; Zeng et al., 2010) . However, it is not known if the action of PP6 on any of these substrates explains how the reported melanoma-associated changes in PPP6C promote tumour development. Here we set out to explain how mutations in PPP6C result in altered regulation of PP6 substrates. To do this we first define the consequences of mutations in PPP6C for PP6 enzyme stability and activity, and then develop an unbiased proteomic screen that identifies Aurora-A as the key substrate of PP6 in dividing cells. Using engineered stable cell lines and PPP6C mutant primary melanoma cells we show that Aurora-A is dysregulated when PP6 activity is perturbed and that this results in chromosomal instability and DNA damage.
Results

Melanoma-associated loss-of-function mutations in PPP6C
PPP6C is mutated at multiple sites in 9 to 12.4% of melanoma samples tested (Hodis et al., 2012; Krauthammer et al., 2012; Stark et al., 2012) . It has been argued by one study that the observed pattern of change is characteristic of gain-of-function mutations, although this is speculative since in all cases the functional consequences of these alterations are currently unknown (Hodis et al., 2012) . To better understand the potential effect of these mutations, a homology model for PP6 was created using a sequence-structure comparison strategy (Shi et al., 2001; Yang et al., 2012) (Fig. 1A ). This analysis of the subunits comprising PP6 hinted at their likely roles and structures. As expected the PP6 catalytic subunit PPP6C showed a high degree of sequence homology to PP2A and PP1 catalytic subunits (Shi, 2009) . Intriguingly, the SAPS subunits are likely to be equivalent to the B56 subunit of PP2A involved in substrate recognition ( Fig. 1A ; supplementary material Fig. S1A ). Finally, the ANKRD subunits of PP6 are predicted to contain .17 ankyrin repeats and are therefore expected to form an extended curved surface (supplementary material Fig. S1B ). This is reminiscent of the PPP1R1 scaffolding subunits of PP2A that have HEAT (huntingtin/elongation factor 3/protein phosphatase 2A/TOR1) repeat motifs (Groves et al., 1999; Xing et al., 2006) . We therefore propose that the PP6 ANKRD subunit forms a platform upon which the catalytic and SAPS regulatory subunits sit, shown schematically in the model as a grey outline (Fig. 1A) .
Most important for this work, a homozygous mutation at position 340 (C to T) of the PP6 catalytic subunit (PPP6C) changing histidine 114 into a tyrosine has been observed in multiple independently isolated malignant melanoma samples (Hodis et al., 2012; Stephens et al., 2004; van Haaften et al., 2009) . Although widely conserved in PP2A and PP1 catalytic subunits and in close proximity to the catalytic centre, histidine 114 does not form part of the network of residues interacting directly with the bound manganese ions Fig. 1A) , and a direct role in catalysis or metal binding is therefore unlikely (Shi, 2009) . However, the high degree of conservation suggests it is essential for phosphatase function and therefore may be important for the assembly of the active holoenzyme.
To test these possibilities, recombinant PP6 holoenzymes were purified containing either wild type PPP6C, the PPP6C tumour mutant H114Y, a wide panel of PPP6C tumour mutations (Hodis et al., 2012; Krauthammer et al., 2012) , or a phosphatase dead version of PPP6C containing two mutations abrogating binding of the metal ions required for catalysis. Western blot analysis of the phosphatase complexes isolated using the different versions of the catalytic subunit showed that in contrast to the wild-type PPP6C, PPP6C-H114Y did not efficiently co-precipitate the PP6 SAPS2 or ANKRD28 subunits (Stefansson and Brautigan, 2006) (Fig. 1B) . Previous studies have shown that PP2A, PP4 and PP6 catalytic subunits interact with alpha4, a chaperone transiently required to protect the PP2A family catalytic subunits from degradation until the holoenzyme complex has been assembled (Kong et al., 2009; Prickett and Brautigan, 2006) . Catalytic subunits unable to associate with the regulatory subunits are expected to show stronger association with alpha4 but to be eventually degraded by the proteasome. As expected, alpha4 was not present in wild-type PP6 holoenzymes, but was found to stably precipitate with PPP6C-H114Y (Fig. 1B) , supporting the idea that regulatory subunit binding and alpha4-binding are mutually exclusive (Kong et al., 2009) . Consistent with increased degradation of PPP6C-H114Y, the levels of this protein were stabilised by the proteasome inhibitor MG132 (Fig. 1C) . Low levels of alpha4 were also present in the PPP6C-PD complexes (Fig. 1B) and PPP6C-PD was also stabilised by the addition of MG132 (Fig. 1C) , suggesting PPP6C-PD has a partial assembly defect. Consistent with this idea PPP6C-PD complexes contain normal levels of SAPS2 but lack ANKRD28 (Fig. 1B) . In contrast, PPP6C-H114Y lacks both the SAPS2 and ANKRD28 subunits (Fig. 1B) . Furthermore, only the wild-type PPP6C efficiently dephosphorylated the generic phosphatase substrate p-nitrophenylphosphate (Fig. 1D ). PPP6C-H114Y showed little activity above the background value observed with a buffer control or the catalytically inactive PPP6C-PD (Fig. 1D ). Extending these results, a similar loss of interaction with the SAPS2 regulatory subunit (Fig. 1E ) and reduction in PP6 catalytic activity ( Fig. 1F ) was observed for a wider panel of melanomaassociated mutations in PPP6C. Compromised PP6 holoenzyme assembly and catalytic activity are therefore features generally associated with the melanoma-associated mutations in PPP6C, and in at least one case, PPP6C-H114Y, this also destabilises the catalytic subunit and results in its turnover by the proteasome. This agrees with the proposal that PPP6C mutations are loss-rather than gain-of-function (Krauthammer et al., 2012) . Because of these effects, tumour cells carrying PPP6C mutations will therefore lack PP6 catalytic activity leading to dysregulation of PP6 substrates. Testing whether or not this is of significance for the development of the tumour requires a definitive identification of the cellular pathways in which PP6 functions and the target proteins it acts on.
Unbiased identification of cellular targets for PP6 in mitosis
Current procedures for identifying the substrates of many enzymes rely on candidate approaches and other inherently biased strategies. Using such candidate approaches PP6 has previously been reported to act in the regulation of NF-kappaB, DNA-PK, histone c-H2AX and Aurora-A (Douglas et al., 2010; Mi et al., 2009; Stefansson and Brautigan, 2006; Zeng et al., 2010) . However, because of the limitations already mentioned it remains unclear if these reflect the major functions for PP6 that could promote tumorigenesis. Here we describe a procedure for the identification protein phosphatase substrates that overcomes these limitations and apply it to the identification of PP6 substrates in dividing cells. The principle is based on the observation that phosphorylation is rapidly lost in samples incubated on ice for 2 hours after lysis if relevant inhibitors are absent, but is retained if the enzyme responsible for dephosphorylation is inactivated by mutation or depleted from the cells used to make the lysate (Zeng et al., 2010) . This can be exploited in the form of a general unbiased method to identify the substrates of phosphatases. Whole cell extracts from phosphatase active and inactive states were subjected to in-solution digestion followed by strong-cation exchange chromatography and titanium dioxide phosphopeptide enrichment steps prior to reverse phase online-LC mass spectrometry ( Fig. 2A) .
Phosphopeptides in the different conditions were identified and filtered using an analysis pipeline created with the OpenMS software ( Fig. 2A ; supplementary material Fig. S2 ) (Kohlbacher et al., 2007) . Candidate PP6 substrates were defined as those phosphopeptides lost in the control and untreated samples but protected in samples depleted of the PP6 catalytic (PPP6C) and regulatory (SAPS) subunits and by the PPP inhibitor okadaic acid. (Hodis et al., 2012; Krauthammer et al., 2012) . The enlarged region of the catalytic centre shows the interaction (dotted grey lines) of the side chains of Asn113, His163 and His237, and Asp53, His55 and Asp81 with the two manganese ions. One of these residues, His55 (magenta) is mutated in tumours (Krauthammer et al., 2012) . Alignment of the PPP family catalytic subunits shows that His114 is invariant in all family members, but the model suggests that is not directly involved in metal ion binding. It is predicted to form a salt bridge (dotted yellow line) to Asp84, and might therefore be structurally important for positioning two of the catalytic residues, Asp81 and Asn113, and the a5-a6 helices. (B) PP6 holoenzymes were prepared from HeLa Flp-In cells stably expressing inducible FLAG-tagged wild-type PPP6C, phosphatase dead (PD) or PPP6C H114Y. Purified holoenzyme complexes were blotted for PPP6C, the PP6 SAPS2 and ANKRD28 subunits, and the alpha4 PPP catalytic subunit chaperone. (C) HeLa cells stably expressing inducible FLAG-tagged PPP6C constructs were induced with doxycycline (Dox) for 12 hours, and then treated with MG132, as indicated, prior to cell lysis. Cell lysates were blotted for PPP6C or actin as a loading control. (D) PP6 holoenzymes were tested for activity towards the generic phosphatase substrate p-nitrophenol (pNPP). Absorbance at 405 nm is plotted in the graph, error bars indicate the standard deviation (n53). (E) PP6 holoenzymes were prepared from HEK293 cells transfected with FLAG-tagged wild-type PPP6C, phosphatase dead (PD), PPP6C H114Y, S167F, R264C, S270L, K132N, P186S, P259S, G52K, H55Y, L110F, G112E, Q189R and L305F. The purified holoenzyme complexes were western blotted for PPP6C, and the PP6 SAPS2 and ANKRD28 subunits. (F) PP6 holoenzymes were tested for activity towards the generic phosphatase substrate p-nitrophenol (pNPP). Activity relative to the control (set to 1.0) is plotted in the graph, error bars indicate the standard deviation from the mean (n52).
This analysis identified 198 phosphorylation sites protected in both PPP6C-depleted cells and by okadaic acid treatment, and 450 phosphorylation sites protected in both SAPS depleted cells and by okadaic acid treatment (Fig. 2B ). These sites mapped to 122 and 258 peptides, respectively, of which two were common to both datasets (supplementary material Table S1 ). Filtering for Whole cell extracts were prepared as described in the methods from phosphatase active (siControl and untreated) and inactive states (okadaic acid treated, siPPP6C, siSAPS/PPP6R). These lysates were then subjected to in-solution digestion followed by strong-cation exchange chromatography (SCX) and titanium dioxide phosphopeptide enrichment steps. This generated 58 fractions for analysis by reverse phase online-LC collision-induced dissociation (CID) mass spectrometry. The resulting data files were analysed using a combined Mascot and OpenMS pipeline (supplementary material Fig. S1 ). (B) This analysis identified 31,884 phosphorylation sites. Venn diagrams show the number of phosphorylation sites identified in the different conditions. Note: some peptides contain more than one phosphorylation site. (C) Mass spectra for the candidate Aurora-A T-loop phosphopeptide identified using GAPS. The regions for the double-and triple-charged peptide envelopes at m/z 1152.04 and 768.36 are shown. (D) MS 2 spectra from the siPPP6C and siSAPS/PPP6R samples, confirming the peptide sequence and position of the phosphorylation site at T288. high quality Mascot identification and feature assignments left a single phosphopeptide species identified in two different charge states, the Aurora-A T-loop peptide (supplementary material Table S1 ). The other lower confidence assignment excluded due to low feature quality and Mascot scores was the DNA damage repair protein XRCC1 (supplementary material Table S1 ).
Comparison of the original mass spectra for the double-charged Aurora-A peptide m/z51152.04 shows it is protected only in the samples where PP6 is inactive (Fig. 2C ) and that the phosphorylation maps to T288 (Fig. 2D) . Similar results were obtained for the triple-charged Aurora T-loop peptide m/z 5768.36 (Fig. 2C) . Blotting confirmed that the Aurora-A T288 residue is dephosphorylated in the absence of phosphatase inhibitors, as are other phosphoproteins PRC1 and MPS1 (Fig. 3A) . However, only Aurora-A T288 phosphorylation was protected by both okadaic acid treatment and depletion of PPP6C or the SAPS regulatory subunits (Fig. 3B ). By contrast, PRC1 dephosphorylation at T481 (Mollinari et al., 2002) was prevented by okadaic acid treatment, but still occurred in extracts lacking PP6 activity (Fig. 3B ). The PRC1 T481 phosphopeptide was also identified by mass spectrometry in the list of peptides protected only in okadaic acid treated samples.
These findings show that dephosphorylation of Aurora-A at T288 requires PP6. To prove that this is a direct consequence of PP6 activity, recombinant PP6 holoenzyme complexes containing either wild-type or mutant catalytic subunits were incubated with Aurora-A-TPX2 complex purified from mitotic cells. In this assay, wild-type PP6 but not a non-specific phosphatase (CIP) readily dephosphorylated T288-phosphorylated Aurora-A ( Fig. 3C ) (Bayliss et al., 2003; Zeng et al., 2010) . No dephosphorylation of Aurora-A T288 was observed with PP6-PD or PP6-H114Y (Fig. 3C) , and similar results were seen with another tumour mutation S167F (supplementary material Fig. S3A ). PP6 activity is therefore necessary and sufficient for the dephosphorylation of activated Aurora-A. Furthermore, these results indicate that the PPP6C-H114Y and other tumour-associated loss-of-function mutations will lead to a specific amplification of Aurora-A activity.
Aurora-A activity is amplified in cells expressing PP6 H114Y
The results presented thus far indicate that the tumour-associated PPP6C-H114Y mutation renders the PP6 catalytic subunit unable to interact with the regulatory subunits and therefore leads to a PP6 null state in which Aurora-A activity should be amplified. To test the effect of the PPP6C-H114Y mutation on Aurora-A localisation and activity, matched cell lines were created containing a single integrated copy of a doxycycline-inducible FLAG-tagged PPP6C wild-type, PPP6C-PD or PPP6C-H114Y. These transgenes carry silent mutations rendering them resistant to the PPP6C siRNA duplex 08. When induced with doxycycline and treated with siPPP6C08 these cells replace the endogenous PPP6C with the form encoded by the transgene. In control cells, activated Aurora-A detected by the phosphorylated T288 antibody was tightly concentrated around the mitotic spindle poles (Fig. 4A, arrowheads) , and the Aurora-A regulated spindle assembly factor NuMA was recruited to the mitotic spindle ( Fig. 4B) (Kettenbach et al., 2011) . By contrast, in cells depleted of PPP6C the staining of both Aurora-A and T288 phosphorylated Aurora-A was elevated and spread along the spindle microtubules (Fig. 4A, arrows) , and NuMA was lost from the spindles as a consequence (Fig. 4B ). Under these conditions the organisation of the chromatin and mitotic spindle was also altered (Fig. 4A) . Replacement of wild-type PPP6C by H114Y or Fig. 3 . PP6-H114Y lacks Aurora-A phosphatase activity. (A) HeLa cell lysates were prepared in lysis buffer lacking okadaic acid (OA). Samples were incubated on ice for 2 hours and okadaic acid was added at the times shown. All samples were blotted with phosphospecific antibodies against Aurora-A (pT288), PRC1 (pT481), and antibodies against Aurora-A, PRC1 and MPS1. MPS1 is phosphorylated at multiple sites during mitosis and this reduces its mobility (Dou et al., 2011) . Increased mobility, shown by a downshift on SDS-PAGE can therefore be used as a marker for MPS1 dephosphorylation. Tubulin and cyclin B were used as loading controls. (B) HeLa cells were transfected for 48 hours with control, PPP6C si08 or SAPS1/2/3 siRNA (siPPP6R) duplexes. Lysates were then prepared from these cells in lysis buffer containing (+) or lacking (2) okadaic acid in the combinations shown in the figure. After 2 hours incubation on ice the samples were blotted using the antibodies shown. (C) Purified Aurora-A-TPX2 complexes were incubated with wild-type or catalytically inactive recombinant PP6 holoenzymes, PP6-WT, and PP6-PD and PP6-H114Y, respectively, buffer, mock purified enzyme, or 2.5 units calf intestinal phosphatase (CIP) for 2 hours then blotted as shown in the figure. S167F mutant forms caused the same spread of Aurora-A and the active form of Aurora-A along the mitotic spindle (Fig. 4A , arrows and S3B), and NuMA was also lost from the mitotic spindle ( Fig. 4B and supplementary material Fig. S3C ). These results support the notion that Aurora-A activity is increased in cells expressing PPP6-H114Y or S167F. To confirm this idea Aurora-A-TPX2 complexes were isolated from cells expressing wild-type and mutant forms of PPP6C and their activity tested using in vitro kinase assays. This approach revealed that there is a 200-250% increase in Aurora-A activity in cells expressing PPP6C-H114Y or the PPP6C-PD catalytic mutant when compared to control cells (Fig. 4C) . The overall level of activated T288 phosphorylated Aurora-A was also increased under these conditions (Fig. 4C) . Together, these results show that when PP6 function is compromised by the PPP6C-H114Y mutation Aurora-A targeting to the mitotic spindle is increased and Aurora-A activity is amplified.
To extend key aspects of these findings LB373-MEL primary melanoma cells homozygous for the PPP6C H114Y mutation were then compared to a control melanoma cell line LB2518-MEL carrying wild-type PPP6C (Stephens et al., 2004; van Haaften et al., 2009 ). In agreement with biochemical analysis of PPP6C-H114Y mutant stability (Fig. 1C) , LB373-MEL tumour cells showed reduced levels of PPP6C compared to the LB2518-MEL control cells and an upshifted T288 phosphorylated form of Aurora-A (Fig. 5A) . When lysates were prepared in the absence of phosphatase inhibitors, Aurora-A remained in a phosphorylated state in LB373-MEL cells but was rapidly dephosphorylated in control LB2518-MEL melanoma cells (Fig. 5B) , demonstrating that the absence of PPP6C protein in LB373-MEL also leads to functional loss of the Aurora-A T-loop phosphatase. These cells also showed greatly increased micronucleation relative to LB2518-MEL control cells (Fig. 5C) , fitting with the idea that they have mitotic defects and are genomically unstable as a consequence. The LB373-MEL cells also showed increased levels of total and pT288 activated Aurora-A at the mitotic spindle relative to the LB2518-MEL cells (Fig. 5D ). Confirming the idea that LB373-MEL cells display an Aurora-A amplification phenotype, limiting inhibition of Aurora-A with the specific drug MLN8537 significantly (P,0.001) reduced the extent of micronucleation by nearly 25% (Fig. 6A,B) . Interestingly, the same treatment caused a slight but significant (P,0.001) 7.3% increase in nucleation in the LB2518-MEL cells, suggesting that reduced Aurora-A activity also leads to increased genome instability (Fig. 6A,B) .
Together, these results from engineered model cell lines and primary tumour cells provide compelling evidence that mutations in PPP6C can result in altered Aurora-A regulation and genome instability. One caveat is the difficulty of proving that the micronucleation phenotype observed in LB373-MEL cells is a direct consequence of the loss of PP6 activity due to the acquisition of inactivating mutations in PPP6C. To investigate whether reduction of PP6 activity directly induces micronucleation and chromosomal instability, engineered cell lines where the PP6 catalytic subunit can be rapidly replaced by wild-type or mutant forms were therefore used.
Loss of PP6 function results in chromosome instability
Replacement of endogenous PPP6C with a wild-type si08
Res PPP6C WT transgene did not result in any alterations in Flp-In cell lines containing a single integrated copy of a doxycycline-inducible FLAG-tagged PPP6C wild-type or H114Y were transfected with control or PPP6C08 siRNA duplexes for 24 hours, then induced with doxycycline for 24 hours. The cells were fixed, and then stained with antibodies for (A) Aurora-A, T288 phosphorylated Aurora-A (pT288) and tubulin, or (B) NuMA and tubulin. DNA was stained with DAPI. Scale bars: 10 mm. (C) Histone H3 kinase assays were performed using Aurora-A-TPX2 complexes purified from cells expressing only PPP6C wild-type, phosphatase dead (PD) or PPP6C-H114Y. In addition, incubations using a mock isolation (control) and a buffer control were performed. Radioactive incorporation into histone H3 ([ 32 P]H3) was measured and is plotted in the graph; error bars show the standard deviation (n53). A paired Student's t-test indicated a significant (**P50.011) difference in kinase activity between wildtype control and PPP6C-H114Y conditions. A Coomassie-Blue-stained gel shows equal loading of histone H3. Samples were also blotted for Aurora-A and T288 phosphorylated Aurora-A (pT288).
nuclear morphology (Fig. 7A ) or increased micronucleation (Fig. 7B) . When the transgene was not induced, or both endogenous and transgene expressed PPP6C was depleted using siPPP6C07 nuclear morphology was altered and the cells became micronucleated (Fig. 7A,B) . Replacement of endogenous PPP6C with the si08
Res PPP6C H114Y resulted in the formation of multilobed nuclei (Fig. 7A ) and caused micronucleation in 50% of cells (Fig. 7B) . Similar effects were seen when a catalytically inactive si08
Res PPP6C PD transgene was used (Fig. 7A,B) . The formation of micronuclei is consistent with the idea that chromosome segregation is perturbed in these cells and that PPP6-H114Y causes chromosome instability. To directly test the idea that reduction of PP6 activity promotes chromosomal instability, fluorescence in-situ hybridisation (FISH) was performed using probes directed towards chromosomes 2 and 8. The parental cell line is known to be triploid for these chromosomal loci (Macville et al., 1999) and this was confirmed by the analysis (Fig. 7C) . By contrast, chromosomes 2 and 8 showed altered segregation in the absence of PP6 function, with ,5% single chromosome mis-segregation events for either one of these loci resulting in 10.6-10.7% cells with altered chromosome number (Fig. 7C ).
Elevated chromosome instability in PPP6C mutant primary tumour cells
To further support the idea that PPP6 mutation results in chromosome instability, primary melanoma cell lines were analysed. FISH was performed using probes for chromosomes 2 and 8, or 7 and 15 in the PPP6C mutant melanoma cell line LB373-MEL, the PPP6C wild-type melanoma cell line LB2518-MEL and control diploid RPE1 cells. As expected, the control RPE1 cells were diploid and analysis of both chromosomes 2 and 8 or 7 and 15 showed fewer than 5% of cells had a non-modal chromosome number (Fig. 8A and supplementary material Fig.  S4 ). The PPP6C wild type melanoma cells line had altered copy number for all chromosomes tested, and 20-25% of cells displayed a non-modal chromosome number ( Fig. 8A and  supplementary material Fig. S4 ). Strikingly, up to 80% of the LB373-MEL PPP6C-H114Y mutant melanoma cells had a nonmodal chromosome number ( Fig. 8A and S4 ). This high level of cells with a non-modal chromosome number reflected a statistically significant (P,0.001) increase in chromosome instability, when compared to an equivalent PPP6C wild-type melanoma (Fig. 8A ). This pattern of chromosome instability is consistent with the high frequency of micronucleation observed in the LB373-MEL PPP6C-H114Y cells and the low level seen in the LB2518-MEL PPP6C wild-type cells (Fig. 5C ). These data therefore support the hypothesis that mutation of PPP6C and consequent loss of PP6 function correlate with increased chromosomal instability and therefore directly promote the formation of micronuclei.
Micronucleation and DNA damage as a consequence of reduced PP6 activity
Although there is strong evidence to suggest that chromosomal instability promotes tumorigenesis, the precise molecular mechanisms are unclear. An influential study on the origins of chromothripsis, the catastrophic re-arrangement of single chromosomes or chromosome arms in cancer cells and considered a catalyst or driver for tumour evolution, has suggested that micronucleation induced by chromosomal Lysates were blotted for Aurora-A pT288 and total Aurora-A. The change in Aurora-A pT288 was measured, normalized to total Aurora-A, and plotted on the graph; error bars show the standard deviation (n53). An independent sample Student's t-test indicated a significant (**P50.018) difference in Aurora-A phosphorylation between LB2518-MEL control and LB373-MEL PPP6C-H114Y cells in the absence of phosphatase inhibitors. Compared with the control LB2518-MEL cells, no significant reduction in Aurora-A phosphorylation occurred in the absence of phosphatase inhibitors in LB373-MEL (P50.513). (C) LB373-MEL and matched control LB2518-MEL cells were fixed and stained with CREST serum to detect centromeres and kinetochores, and DAPI to detect DNA. Cells with CREST-positive micronuclei, indicating chromosome segregation defects in mitosis, were counted. This is expressed as a percentage, with standard deviation for three independent experiments and shown on the images in the figure. (D) LB373-MEL and matched control LB2518-MEL cells in mitosis were stained for Aurora-A and pT288 Aurora-A. DAPI was used to detect DNA. Scale bars: 10 mm.
instability may be one such trigger (Crasta et al., 2012; Forment et al., 2012; Stephens et al., 2011) . Such micronuclei are defective and delayed in DNA replication, resulting in DNA damage and premature DNA condensation (Crasta et al., 2012) . However, how this would be initiated or what the drivers for these events could be was not investigated.
To test whether loss of PP6 function induces micronuclei exhibiting DNA damage, PPP6C-depleted HeLa cells were stained with antibodies against the Ser139-phosphorylated form of histone H2A.X (c-H2AX), an early marker for DNA damage (Rogakou et al., 1998) (Fig. 8B) . In these cells, loss of PPP6C resulted in a significant increase in c-H2AX-positive micronuclei (Fig. 8B) . Similar results were obtained in the primary tumour cells lines, LB373-MEL PPP6C-H114Y mutant melanoma cells showed a significant increase in c-H2AX-positive micronuclei relative to the matched control (Fig. 8C) , consistent with the view that chromosomal instability combined with micronucleation results in DNA-damage. Together, these observations reveal that loss of PP6 results in a significant increase in chromosomal instability, micronucleation and DNA damage, and suggest an attractive explanation of why mutations in PPP6C may act as driver mutations in UV-induced skin cancer (Hodis et al., 2012; Krauthammer et al., 2012) . PPP6C  H114Y ) forms of PPP6C tagged at the N-terminus with a FLAG epitope were transfected with control or si07 and si08 duplexes targeting PPP6C for 48 hours. Doxycycline (1 mg/ml) was included in the growth medium for the last 24 hours to induce expression of the transgenes. The cells were fixed and then stained with DAPI, or blotted for PPP6C and actin as a loading control. (B) Micronucleation and abnormal nuclear morphology was scored for each condition and is plotted in the graph. Error bars indicated the standard deviation from the mean (n53). (C) Control and PPP6C-depleted cells were analyzed using FISH with probes for loci on chromosomes 2 and 8. Synchronized cells were used to allow the analysis of the products of a single round of mitosis. Examples images are shown, with chromosome 2 marked in red and chromosome 8 marked in green. The frequency of chromosome mis-segregation was counted for the progeny of 1000 mitotic events in all conditions and plotted on the graphs. Because the cells are stably triploid at the outset this category is not shown. Scale bars: 10 mm.
Discussion
If Aurora-A is an oncogene, is PPP6C a tumour suppressor?
All of the mutations tested resulted in defective assembly of PP6 holoenzyme complexes and are therefore expected to result in reduced enzyme activity. For the PPP6C-H114Y mutation, where a primary tumour cell line exists, it was confirmed that this change leads to activation of the major PP6 substrate, Aurora-A. Based on these findings, PPP6C could therefore be considered a candidate tumour-suppressor gene, opposing Aurora-A already classified as an oncogene (Bischoff et al., 1998) . Corroborating these findings, PPP6C has recently been identified as 'driver gene' for melanoma (Hodis et al., 2012; Krauthammer et al., 2012) . Mutations in a 'driver gene' are thought to confer a selective advantage to an emerging tumour and are thus distinct from 'passenger' mutations that do not confer a selective advantage. Our work provides a biological basis explaining why mutations in PPP6C have 'driver' properties: they destabilize the PP6 holoenzyme and result in amplified Aurora-A activity, which in turn perturbs efficient chromosome congression and segregation.
Although chromosome instability has long been recognized as a hallmark and potential driving force of human cancers (Boveri, 2008; Holland and Cleveland, 2012; Lengauer et al., 1998; McGranahan et al., 2012) , the mechanisms behind chromosome instability in tumours continue to be largely unexplained. The analysis of tumour-associated PPP6C mutations and their biological consequences demonstrates how chromosome instability may arise. Importantly, loss of PP6 function not only Modal chromosomal number was calculated for each cell line, and individual cells were then classified as having the modal or a non-modal chromosomal number (error bars show the standard deviation, n52). Using either the chromosome 2 and 8, or the chromosome 7 and 15 datasets, cell lines were compared in pairwise fashion using a Chi-squared test. Bonferroni correction was applied to account for pairwise testing, with P,0.0166 representing significance at the 5% level. (B) HeLa cells were depleted of PPP6C by siRNA for 60 hours were stained with antibodies to c-H2A.X and CREST serum. DNA was visualized with DAPI. (C) LB2518-MEL and LB373-MEL cells were stained with antibodies to c-H2AX and DNA was visualized with DAPI. In both B and C the number of c-H2AX-positive micronuclei were counted (600 cells from three different experiments, error bars indicate standard deviations). (D) In this model PPP6C loss-of-function mutations result in chromosome instability combined with micronucleation due to a failure to properly segregate chromosomes to a single defined nucleus. Although chromosome instability alone promotes aneuploidy, chromosome instability combined with micronucleation results in DNA damage to those chromosomes present in the micronucleus, which is reminiscent of the process of chromothripsis. Scale bars: 10 mm. results in chromosome instability, it also promotes micronucleation due to defective chromosome segregation (Zeng et al., 2010) , which emerging evidence shows is the origin of a phenomenon termed chromothripsis or chromosome shattering (Crasta et al., 2012; Forment et al., 2012) . This type of genomic re-arrangements is thought to contribute significantly to tumour evolution however how it is initiated remains mysterious. The findings presented here support the view that it is the combination of chromosome instability and micronucleation, with resulting DNA damage that may explain why PPP6C mutations act as drivers in melanoma. These ideas can be summarised in the following scenario for PPP6C mutations in UV-induced skin cancer progression (Fig. 8D) . Exposure of skin cells to UV results in undirected DNA damage at a variety of loci. Specific mutations in the coding region for PPP6C result in loss of PP6 catalytic activity as well as reduced protein stability. These cells will enter mitosis with amplified Aurora-A activity, resulting in impaired spindle formation, chromosome segregation errors and thus micronucleation as we have shown previously (Zeng et al., 2010) . Micronuclei are impaired in their DNA replication capacity due to limiting number of nuclear pores and structural defects in the nuclear envelope (Géraud et al., 1989; Hoffelder et al., 2004) . These cells will therefore undergo successive rounds of mitosis with under-replicated micronuclear DNA driving chromosome fragmentation as a consequence (Crasta et al., 2012) . The resulting DNA damage provides a mechanism to promote tumorigenesis, since within a population of such cells there are likely to be a number with one or more additional driver mutations. We therefore propose that loss of PP6 activity predisposes cells to chromothripsis and tumorigenesis through the pronounced accumulation of micronuclei in an Aurora-A-dependent fashion.
Identification and management of PPP6C mutant tumours
As already discussed, Aurora-A is amplified in many cancers and is currently the focus of much interest as a drug target for cancer therapy (Bischoff et al., 1998; Karthigeyan et al., 2010; Sen et al., 1997; Zhou et al., 1998) . As we show, loss of PP6 function leads to increased Aurora-A activity and creates a state similar to direct amplification of the Aurora-A locus. Aurora-A inhibitors may therefore prove valuable to treat cancers with dysregulated PPP6C, with the caveat that they increase genome instability in normal cells. An intriguing immediate possibility is that Aurora-A inhibitors already in clinical trials could be used at low doses to help manage amplified Aurora-A activity in PPP6C mutant tumours. This would require the development of simple screens for changes in PPP6C, but as we have shown here, these mutations appear to destabilize the protein and immunohistochemistry could therefore be used to detect reduction or loss of PPP6C in tumour biopsies.
Materials and Methods
Reagents and antibodies
Laboratory reagents were obtained from Thermo Fisher Scientific and SigmaAldrich. Commercial antibodies were used to detect a-tubulin (mouse, DM1A; Sigma-Aldrich), Aurora-A (rabbit, AB12875; Abcam), phospho-Aurora-A pT288 (rabbit 3079; Cell Signaling Technology), pan phospho-Aurora-A/B/C pT288/232/ 198 (rabbit, 2914; Cell Signaling), phospho-PRC1 T481 (goat, sc-11768, Santa Cruz), PPP6C (rabbit, A300-844A; Bethyl Laboratories, Inc.), SAPS1-3 (rabbit, A300-968A, A300-969A and A300-972A; Bethyl), MPS1/TTK (mouse, [N1], ab11108; Abcam), TPX2 (mouse, ab32795; Abcam) and cyclin B1 (mouse, GNS3; Millipore). Affinity purified primary and secondary antibodies were used at 1 mg/ ml final concentration and sera were used at 1:1000 dilution. Secondary antibodies, raised in donkey, to mouse, rabbit and sheep/goat conjugated to HRP, Alexa Fluor 488, Alexa Fluor 555, Alexa Fluor 568 and Alexa Fluor 647 were obtained from Molecular Probes.
Cell culture and microscopy LB2518-MEL and LB373-MEL melanoma primary cell lines were cultured in Iscove's medium supplemented with 10% fetal calf serum, AAG (0.24 mmol/L of L-asparagine, 0.55 mmol/L of L-arginine, 1.5 mmol/L of L-glutamine) and HITES (10 nM hydrocortisone, 5 mg/ml insulin, 100 mg/ml transferrin, 10 nM 17-bestradiol, 30 nM sodium selenite). Stable HeLa cells were created as described previously and cultured in growth medium (DMEM containing 10% foetal bovine serum) at 37˚C and 5% CO 2 (Bastos et al., 2012) . For plasmid transfection and siRNA transfection, Mirus LT1 (Mirus Bio LLC) and Oligofectamine (Invitrogen), respectively, were used according to the manufacturer's instructions. Microscopy was performed exactly as described elsewhere (Dunsch et al., 2012) .
Homology modelling
Homology models for the PPP6C and SAPS1 subunits of PP6 were built using FUGUE to carry out sequence-structure comparison (Shi et al., 2001) . For PPP6C the best match was seen to the PP1 and PP2A catalytic subunits structures, and the PDB structure 1tcoa was used for model building. For SAPS1 a good match was seen with the PP2A-B56 regulatory subunit in PDB structure 3fgab. Homology models were refined with Modeller and Chimera (http://www.cgl.ucsf.edu/ chimera) (Pettersen et al., 2004; Yang et al., 2012 ) then exported to Pymol 1.5.0.5 to create figures (The PyMOL Molecular Graphics System, Version 1.5.0.5 Schrödinger, LLC.).
Isolation of peptides from whole mitotic cell extracts
Proteins were isolated from cells arrested in mitosis with 100 ng/ml nocodazole for 16 h. Mitotic cells were harvested by shake off, washed three times with warm PBS and then re-suspended in warm growth medium. Cells were incubated in a 5% CO 2 incubator at 37˚C for 20 min and then washed twice with cold PBS. The cells were lysed in a buffer containing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% sodium deoxycholate and 1:250 protease inhibitor cocktail (Sigma), left on ice for 75-100 min, then centrifuged at 21,000 g for 15 min at 4˚C to remove insoluble debris. Lysates containing 25 mg of mitotic cell protein extract were mixed with five volumes 100% trichloroacetic acid (TCA) and incubated overnight on ice. Precipitates were centrifuged for 8 min at low speed (1006g) then washed twice with ice-cold acetone. The pellets were dried at 37˚C to remove acetone and re-suspended in 10 ml UA (8M urea, 100 mM Tris-HCl [pH 8.5]) with 100 mM dithiothreitol (DTT) and loaded into Amicon Ultra 15 30 kDa spinconcentrators (Millipore) for tryptic digestion by filter-aided sample preparation (Wiśniewski et al., 2009) . After 20-fold concentration at 47006g, 10 ml UA was added and the sample concentrated again. Concentrates were then mixed with 2 ml of 50 mM iodoacetamide (IAA) in UA buffer and incubated at room temperature (RT) for 30 min then centrifuged for 45 min. Concentrates were resuspended in 10 ml of 50 mM ammonium bicarbonate (Ambic) and the concentration process repeated twice to remove urea. Trypsin, 4 ng/ml final concentration, was added to the final concentrate and digestion performed at 37˚C overnight. Tryptic peptides were collected by centrifugation for 10 min at 36006g. Two further elutions with 2 ml of 50 mM Ambic were performed and the eluates pooled. Pooled eluates were desalted using 1 g (20 cc) Oasis HLB plus cartridges (part number 186000117, Waters Corporation) according to the manufacturer's instructions. Peptides were eluted with 90% acetonitrile (Acn)/0.5% formic acid, pooled together and vacuum dried.
Phosphopeptide enrichment strategy and mass spectrometry
To enrich phosphopeptides a sequential strategy of strong cation exchange (SCX) chromatography followed by titanium dioxide (TiO 2 ) binding was employed (Olsen and Macek, 2009) . Dried peptides were dissolved in buffer A (5 mM ammonium formate, 20% Acn, acidified with trifluoroacetic acid (TFA) to pH 2.7 and centrifuged for 10 min at 21,0006g at 4˚C prior to loading onto a 1 ml Resource S column (GE Healthcare) via a 5 ml injection loop. Peptides were eluted at 1 ml/min collecting 1 ml fractions by a 20 min linear gradient from 100% buffer A to 50% buffer B (200 mM ammonium formate, 20% Acn, acidified with TFA to pH 2.7) followed by a 5 min linear gradient ramp from 50% to 100% buffer B and a final 5 min with 100% buffer B. Half of each fraction was vacuum dried and reconstituted in 40 ml GA solution (80 mg/ml glycolic acid, 80% Acn and 2% TFA) for TiO 2 -based enrichment of phosphopeptides (Rappsilber et al., 2003; Rappsilber et al., 2007) . A 200 ml pipette tip was plugged with C8 matrix, 4 mg of TiO 2 bead slurry added, equilibrated with 40 ml of 0.6% NH 4 OH and then 40 ml of GA. Peptides were applied to the tips at low flow rate (2000 rpm in a bench-top micro-centrifuge for ,5 min). The tips were washed with 40 ml of GA, 40 ml of a mixture of 80% Acn and 0.2% TFA and finally 40 ml of 20% Acn. Phosphopeptides were eluted first with 40 ml of 0.6% NH 4 OH and 40 ml of 60% Acn and the eluates pooled (80 ml). A second phase of elution, in 40 ml of 1% pyrrolidine, followed by 40 ml of 60% Acn was also carried out. All eluates were dried, re-dissolved in 0.5% formic acid, then analyzed by online LC-MS 2 with a nanoAcquity UPLC system (Waters Corporation) and a hybrid mass spectrometer (LTQ-Orbitrap XL ETD; Thermo Fisher Scientific) fitted with a nanoelectrospray source (Proxeon) as described previously (Zeng et al., 2010) . All spectra were acquired using Xcalibur software (version 2.0.7; Thermo Fisher Scientific).
Data processing using OpenMS
MSConvert (part of MSFileReader version-13_04.14.2009; Thermo Fisher Scientific) was used to convert data files acquired by Xcalibur into mzML format. OpenMS (version 1.8.0) proteomics pipeline (Kohlbacher et al., 2007; Sturm et al., 2008) was used to create a data filtering/analysis procedure to directly compare matched SCX/TiO 2 samples. Data acquired in profile mode were centroided, then MS 1 peaks picked using the high-resolution PeakPicker peakpicking algorithm. Peptide ions with charge states 2 + to 5 + within an intensity range of 5610 4 and 1610 9 were then selected. MS features were then identified with the FeatureFinder centroided data algorithm. Features in the equivalent fractions from different samples were matched together using the FeatureLinker 'unlabelled' algorithm with a maximum allowed RT or m/z difference of 10 seconds or 10 ppm, respectively. The outputs, either siPPP6C, plus OA, siControl, minus OA, or siPPP6R, plus OA, siControl, minus OA were merged into one consensus XML file. Each sample is linked to a numbered consensus 'element map' within this file.
In parallel to the batch processing of data files described already, Mascot (version 2.2.0.3; Matrix Science) was used to search each input mzML data file using the MascotAdapterOnline tool, against the human international protein index database (version 3.60; 79,371 protein entries), producing a corresponding idXML search result file for each SCX fraction/TiO 2 enrichment. Search parameters were: precursor mass tolerance 6 1 Da, and 6 0.8 Da for MS 2 fragmentation spectra, enzyme specificity was set to trypsin with two missed-cleavages, Cyscarbamidomethylation as a fixed modification, and Met-oxidation and phosphorylation of Ser/Thr as variable modifications. The idXML files from parallel SCX/TiO 2 samples were then concatenated using IDMerger. To match features with peptide sequences merged consensusXML files were annotated with the peptide sequence information from the corresponding merged idXML file using TOPPView. Perl scripts were used to extract only PPP6-sensitive phosphorylation events from the data, inserting a 'user parameter metadata tag' (''PP6 substrate'') into the XML file structure if a phosphopeptide is present in the siPPP6C or siSAPS/PPP6R and plusOA, but not in control samples (siGL2 control and untreated/minusOA); that is, only in consensus element maps 0 and 1 but not 2 and 3. A pairwise comparison of candidate phosphopeptides identified in both the siPPP6C and siSAPS/PPP6R (supplementary material Table S1) gives a high confidence lists of PP6 substrates, complete with Mascot scores, feature quality, mass, charge state, LC retention time and intensity values.
Time-course of de-phosphorylation assay
Mitotic cell suspensions prepared as described above were pelleted by centrifugation for 5 min at 300 g and equally divided into ten 1.5 ml microcentrifuge tubes on ice. One cell pellet was immediately lysed in a buffer containing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% sodium deoxycholate, 40 mM b-glycerol phosphate, 10 mM NaF, 1 mM okadaic acid, 1:100 Sigma phosphatase inhibitor cocktail III and 1:250 Sigma protease inhibitor cocktail. The remaining cell pellets were immediately lysed in the same lysis buffer without b-glycerophosphate, NaF, okadaic acid and phosphatase inhibitors. Instead, 1 mM okadaic acid was subsequently added at specific time-points up to 130 min. Cell lysates were then centrifuged for 15 min at 21,0006g to pellet insoluble debris. Cell lysates were kept at 4˚C throughout the whole experimental period. The phosphorylation status of various mitotic proteins was analysed by blotting on normal gels or gels containing 50 mM Phos-tag reagent (Wako Chemicals GmbH, Neuss, Germany) charged with Mn 2+ to better resolve phosphorylated from non-phosphorylated proteins.
Phosphatase and kinase assays
Isolation of recombinant PP6 holoenzyme complexes and Aurora-A-TPX2 complexes were performed exactly as described previously (Zeng et al., 2010) . For p-nitrophenol phosphate (pNPP) phosphatase assays, purified PP6 complexes were incubated with 5 mM pNPP in 50 mM Tris-HCl, pH 8.0, 0.5 mM MnCl 2 , 2 mM DTT for 60 mins at 30˚C. 50 ml reactions were stopped with 200 ml 0.5% SDS and the absorption was read at 405 nm. Phosphatase assays using Aurora-A-TPX2 complexes were performed exactly as described previously (Zeng et al., 2010) . For in vitro kinase assays a modification of a published method was used (Preisinger et al., 2005) . Control or Aurora-A complexes were isolated from 3615 cm dishes of HeLa Flp-in cells each, depleted for endogenous PPP6C using PPP6C siRNA oligo 08 and expressing si08PPP6C wt , si08PPP6C PD or si08PPP6C
H114Y
. Immunoprecipitates were incubated in 50 mM Tris-HCl pH 7.3, 50 mM KCl, 10 mM MgCl 2 , 20 mM b-glycerophosphate, 15 mM EGTA, 100 mM ATP, 0.5 ml [c-32 P]-ATP, 1 mg histone H3 substrate in 20 ml final volume for 30 minutes at 30˚C. Reactions were analysed by SDS-PAGE and autoradiography for histone H3 phosphorylation and blotting for Aurora-A levels.
In situ hybridisation on synchronized cells
For fluorescence in-situ hybridisation, 10 6 cells were seeded in 10 cm dishes then transfected with control or PPP6C siRNA duplexes after 24 hours. After 48 hrs siRNA, the cells were arrested with 2 mM thymidine for 20 hrs, then washed three times in warm PBS and once with fresh growth medium. Mitotic cells were shaken from the dishes after 9-10 hrs, re-seeded on glass slides, then incubated at 37˚C in a 5% CO 2 incubator. After 5-6 hrs, when the cells had attached to the glass and completed mitosis, the slides were treated in hypotonic solution (0.56% KCl) for 30 min at 37˚C, then fixed by dipping in ice cold 3:1 methanol:acetic acid for 30 min changing the fix every 10 min. The slides were air dried overnight then washed with 26SSC (206SSC stock: 17.5 g NaCl and 8.8 g sodium citrate dissolved in 80 ml deionised water, adjusted to pH 7.0 with HCl, and made to a final volume of 100 ml) for 5 min at room temperature. Dehydration was carried out by a series of 2 min washes in 70%, 85% and 100% EtOH. Slides were placed at 37˚C then 2 ml of the FISH satellite enumeration probes for chromosomes 2 and 8 labelled with FITC and Texas-Red (Cytocell Cambridge, UK), respectively, were added in 10 ml hybridization buffer. The liquid was covered with 22622 mm coverslips and the edges sealed with rubber cement. The slides were heated at 76˚C for 3 min using a metal heating block, then kept at 37˚C in a water bath overnight. After removal of the rubber cement and coverslips the slides were washed in 0.256SSC for 2 min at 72˚C, then again in 26SSC with 0.05% [vol/vol] TWEEN20 for 30 sec at room temperature. Finally, the slides were dried and a coverslip mounted over the hybridized region using Moviol 4-88 containing 1 mg/ ml DAPI. Unsynchronised melanoma cells were processed for FISH analysis in the same way but were grown in 12-well micro chambers (ibidi, Martinsried, Germany).
Online supplemental material
Supplementary material Table S1 contains mass spectrometry data for the PPP6C and PPP6R/SAPS activity sensitive phosphopeptides. Supplementary material Figs S1-S4 describe modelling of PP6 scaffold and regulatory subunits, the GAPS processing pipeline and provide additional evidence that melanoma-associated mutations reduces PP6 activity towards Aurora-A. Example batch files for GAPS are provided (supplementary material Fig. S5 ).
